成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  2. Metabolic Enzyme/Protease NF-κB Immunology/Inflammation Apoptosis PI3K/Akt/mTOR Autophagy
  3. HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species Apoptosis Akt Autophagy
  4. Deferoxamine

Deferoxamine  (Synonyms: 去鐵胺; Deferoxamine B; Deferriferrioxamine B; Deferrioxamine)

目錄號(hào): HY-B1625 純度: 99.20%
COA 產(chǎn)品使用指南 技術(shù)支持

Deferoxamine (Deferoxamine B) 是一種鐵螯合劑 (結(jié)合 Fe(III) 和許多其他金屬陽(yáng)離子)，被廣泛用于減少鐵在組織中的積累和沉積。Deferoxamine 具有較好的抗氧化活性，可上調(diào) HIF-1α 水平。Deferoxamine 還具有抗增殖活性，能誘導(dǎo)癌細(xì)胞凋亡和自噬。Deferoxamine 可用于糖尿病、神經(jīng)退行性疾病以及抗癌和抗 COVID-19 的研究。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)

Deferoxamine Chemical Structure

Deferoxamine Chemical Structure

CAS No. : 70-51-9

1.  客戶無(wú)需承擔(dān)相應(yīng)的運(yùn)輸費(fèi)用。

2.  同一機(jī)構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機(jī)構(gòu)（單位）一年內(nèi)

     可免費(fèi)申領(lǐng)三個(gè)不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶。

規(guī)格 價(jià)格 是否有貨 數(shù)量
10 mM * 1 mL in DMSO ￥5316
In-stock
1 mg ￥3080
In-stock
5 mg ￥4310
In-stock
10 mg ￥5170
In-stock
50 mg   詢價(jià)  
100 mg   詢價(jià)  

* Please select Quantity before adding items.

Customer Review

Other Forms of Deferoxamine:

MCE 顧客使用本產(chǎn)品發(fā)表的 234 篇科研文獻(xiàn)

IF
WB
Proliferation Assay
RT-PCR

    Deferoxamine purchased from MCE. Usage Cited in: J Hazard Mater. 2022 Aug 15;436:129043.  [Abstract]

    The specific inhibitor of ferroptosis Fer-1 (100?μM) and Lip-1 (5?μM), and the iron chelator Deferoxamine (DFOM;100?μM) restored the cellular activity of RAW264.7 macrophages after treatment for 24?h.

    Deferoxamine purchased from MCE. Usage Cited in: J Hazard Mater. 2022 Aug 15;436:129043.  [Abstract]

    Deferoxamine (DFOM; 100?μM; 24?h) attenuated the abnormal increase of ROS and LPO in macrophages elicited by CdTe QDs.

    Deferoxamine purchased from MCE. Usage Cited in: Sci Adv. 2022 Mar 4;8(9):eabm1896.  [Abstract]

    PAI1 mRNA expression in iHUVEC treated with increasing doses of either CoCl2, Deferoxamine (DFO), 1, 4-DPCA or DMOG.

    Deferoxamine purchased from MCE. Usage Cited in: Bioact Mater. 2021 Nov 19;13:23-36.  [Abstract]

    H1299 cells are treated with Curcumenol with or without Deferoxamine (DFO; 20 μM) for 24 h, and the cell viability is analyzed.

    Deferoxamine purchased from MCE. Usage Cited in: Bioact Mater. 2021 Nov 19;13:23-36.  [Abstract]

    The expression of ferroptosis-related proteins in lung cancer cells is detected after Curcumenol treatment with or without Deferoxamine (DFO; 20 μM) by western blotting.

    Deferoxamine purchased from MCE. Usage Cited in: Acta Pharm Sin B. 2021 Jun;11(6):1513-1525.  [Abstract]

    Deferoxamine (DFO; 10 μM; 72 h) can markedly reverse the cell growth prevented by a2 in MGC-803 and MKN-45 cells.

    Deferoxamine purchased from MCE. Usage Cited in: Adv Sci (Weinh). 2021 Mar 8;8(10):2004680.  [Abstract]

    Deferoxamine (DFO; 0.5 μM; for 48 h) could rescue iron overload‐induced cell death in both iHep‐Orgs and iHep.

    Deferoxamine purchased from MCE. Usage Cited in: J Exp Clin Cancer Res. 2021 Jun 23;40(1):206.  [Abstract]

    Propidium iodide staining confirmed that DFO inhibited metformin-induced cell death in T47D cells Deferoxamine (20?μM; 48?h).

    Deferoxamine purchased from MCE. Usage Cited in: Signal Transduct Target Ther. 2020 May 8;5(1):51.  [Abstract]

    Representative results of wound healing after the treatment with the combination of ferroptosis inhibitor DFO and erianin. The expression of EMT markers E-Cadherin and N-Cadherin are examined by western blotting.

    Deferoxamine purchased from MCE. Usage Cited in: Theranostics. 2020 Apr 6;10(11):5107-5119.  [Abstract]

    The cell death induced by the treatment with β-elemene and cetuximab in KRAS mutant CRC cells is almost completely blocked by treatment with ferroptosis rescue agents Deferoxamine (DFO; 20?nM; 24?h), Liproxstatin-1 (Lip-1) or Ferrostatin-1 (Fer-1).

    Deferoxamine purchased from MCE. Usage Cited in: J Bone Miner Res. 2020 Jun;35(6):1163-1173.  [Abstract]

    The expression of iron metabolism related protein was assessed by western blot. Protein levels of TfR1, FTH1 and FPN1 in the tibia. BL: The baseline group, mice are raised with under the GMF for 4 weeks. HLU: Mice hindlimb are unloaded and raised for 4 weeks. GMF: Mice are kept in a wooden experimental box with the normal GMF for 8 weeks. HyMF: Mice are raised in a GMF-shielded room for 8 weeks. HLU+GMF: HLU mice are reloaded and raised in a wooden box for 4 weeks. HLU+HyMF: HLU mice are reloade

    Deferoxamine purchased from MCE. Usage Cited in: J Bone Miner Res. 2020 Jun;35(6):1163-1173.  [Abstract]

    The expression of iron metabolism related protein is assessed by western blot. Protein levels of FPN1 and hepcidin1 in the liver. BL: The baseline group, mice are raised with under the GMF for 4 weeks. HLU: Mice hindlimb are unloaded and raised for 4 weeks. GMF: Mice are kept in a wooden experimental box with the normal GMF for 8 weeks. HyMF: Mice are raised in a GMF-shielded room for 8 weeks. HLU+GMF: HLU mice are reloaded and raised in a wooden box for 4 weeks. HLU+HyMF: HLU mice are reloaded

    Deferoxamine purchased from MCE. Usage Cited in: Cell Res. 2018 Dec;28(12):1171-1185.  [Abstract]

    The FTL- or FTH1-knockdown A375 cells are pretreated with or without DFO (50 μM) for 2 h before CCCP stimulation. The pyroptotic morphology and LDH release are indicated.

    Deferoxamine purchased from MCE. Usage Cited in: ACS Appl Mater Interfaces. 2018 Feb 21;10(7):6180-6189.  [Abstract]

    Quantitative analyses confirm the steady increase of blood vessels over the course of implantation of DFO-loading Gp gel.

    查看 HIF/HIF Prolyl-Hydroxylase 亞型特異性產(chǎn)品:

    查看 Akt 亞型特異性產(chǎn)品:

    • 生物活性

    • 純度 & 產(chǎn)品資料

    • 參考文獻(xiàn)

    生物活性

    Deferoxamine (Deferoxamine B) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine upregulates HIF-1α levels with good antioxidant activity. Deferoxamine also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19[1][2][3][4][5].

    細(xì)胞效力
    (Cellular Effect)
    Cell Line Type Value Description References
    A2780 IC50
    3.5 μM
    Compound: DFO
    Antiproliferative activity against human A2780 cells incubated for 72 hrs by MTT assay
    Antiproliferative activity against human A2780 cells incubated for 72 hrs by MTT assay
    		[PMID: 36105345]
    A549 IC50
    7.5 μM
    Compound: DFO
    Antiproliferative activity at human A549 cells after 72 hrs by MTT assay
    Antiproliferative activity at human A549 cells after 72 hrs by MTT assay
    		[PMID: 22861499]
    DMS-53 IC50
    10 μM
    Compound: DFO
    Antiproliferative activity at human DMS53 cells after 72 hrs by MTT assay
    Antiproliferative activity at human DMS53 cells after 72 hrs by MTT assay
    		[PMID: 22861499]
    HCT-116 IC50
    > 200 μM
    Compound: I, DFO
    Dark cytotoxicity against human HCT116 cells expressing wild type p53 after 96 hrs by MTT assay
    Dark cytotoxicity against human HCT116 cells expressing wild type p53 after 96 hrs by MTT assay
    		[PMID: 24900837]
    HCT-116 IC50
    > 200 μM
    Compound: I, DFO
    Dark cytotoxicity against p53-deficient human HCT116 cells after 96 hrs by MTT assay
    Dark cytotoxicity against p53-deficient human HCT116 cells after 96 hrs by MTT assay
    		[PMID: 24900837]
    HeLa IC50
    > 50 μM
    Compound: DFO, desferoxamine
    Cytotoxicity against human HeLa cells after 72 hrs by MTS assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTS assay
    		[PMID: 18345610]
    HepaRG IC50
    50 μM
    Compound: DFO
    Antiproliferative activity against human HepaRG cells after 72 hrs by MTT assay
    Antiproliferative activity against human HepaRG cells after 72 hrs by MTT assay
    		[PMID: 20036563]
    HepaRG IC50
    70 μM
    Compound: DFO
    Antiproliferative activity against human HepaRG cells after 72 hrs by MTT assay in presence of iron(3)
    Antiproliferative activity against human HepaRG cells after 72 hrs by MTT assay in presence of iron(3)
    		[PMID: 20036563]
    HepG2 IC50
    > 100 μM
    Compound: DFO
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 29233652]
    HL-60 GI50
    18.4 μM
    Compound: DFO
    Cytotoxicity against human HL60 cells by alamar blue assay
    Cytotoxicity against human HL60 cells by alamar blue assay
    		[PMID: 23266185]
    HT-29 IC50
    36.1 μM
    Compound: DFO, desferoxamine
    Cytotoxicity against human HT29 cells after 72 hrs by MTS assay
    Cytotoxicity against human HT29 cells after 72 hrs by MTS assay
    		[PMID: 18345610]
    MDA-MB-231 IC50
    6.1 μM
    Compound: DFO
    Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay
    		[PMID: 36105345]
    MDCK IC50
    9.49 μM
    Compound: 1, DFOB
    Toxicity in MDCK cells by MTT method
    Toxicity in MDCK cells by MTT method
    		[PMID: 20041672]
    MRC5 IC50
    > 10 μM
    Compound: DFO
    Antiproliferative activity at human MRC5 cells after 72 hrs by MTT assay
    Antiproliferative activity at human MRC5 cells after 72 hrs by MTT assay
    		[PMID: 22861499]
    MRC5 IC50
    9 μM
    Compound: DFO
    Antiproliferative activity against human MRC5 cells incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MRC5 cells incubated for 72 hrs by MTT assay
    		[PMID: 36105345]
    NIH3T3 IC50
    4.9 μM
    Compound: DFO
    Inhibition of erastin-induced ferroptosis in mouse NIH/3T3 cells after 24 hrs by WST-8 assay
    Inhibition of erastin-induced ferroptosis in mouse NIH/3T3 cells after 24 hrs by WST-8 assay
    		[PMID: 31531196]
    NIH3T3 IC50
    9 μM
    Compound: DFO
    Inhibition of TBHP-induced ferroptosis in mouse NIH/3T3 cells after 12 hrs by WST-8 assay
    Inhibition of TBHP-induced ferroptosis in mouse NIH/3T3 cells after 12 hrs by WST-8 assay
    		[PMID: 31531196]
    SK-N-MC IC50
    10 μM
    Compound: DFO
    Antiproliferative activity at human SK-N-MC cells after 72 hrs by MTT assay
    Antiproliferative activity at human SK-N-MC cells after 72 hrs by MTT assay
    		[PMID: 22861499]
    SK-N-MC IC50
    12.5 μM
    Compound: DFO
    Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay
    Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay
    		[PMID: 22858101]
    SK-N-MC IC50
    14.22 μM
    Compound: DFO
    Antiproliferative activity against human SK-N-MC cells by MTT assay
    Antiproliferative activity against human SK-N-MC cells by MTT assay
    		[PMID: 17963372]
    SK-N-MC IC50
    16.04 μM
    Compound: 1, DFOB
    Toxicity in human SK-N-MC cells by MTT method
    Toxicity in human SK-N-MC cells by MTT method
    		[PMID: 20041672]
    SK-N-MC IC50
    16.81 μM
    Compound: DFO
    Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay
    Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay
    		[PMID: 28841514]
    SK-N-MC IC50
    17.07 μM
    Compound: DFO
    Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay
    Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay
    		[PMID: 22172311]
    SK-N-MC IC50
    17.07 μM
    Compound: DFO
    Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay
    Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay
    		[PMID: 21055950]
    SK-N-MC IC50
    21.63 μM
    Compound: DFO
    Antiproliferative activity against human SK-N-MC cells measured after 72 hrs at 37 degC by MTT assay
    Antiproliferative activity against human SK-N-MC cells measured after 72 hrs at 37 degC by MTT assay
    		[PMID: 23312948]
    SK-N-MC IC50
    22.7 μM
    Compound: DFO
    Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTS assay
    Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTS assay
    		[PMID: 21846118]
    SK-N-MC IC50
    22.7 μM
    Compound: DFO
    Cytotoxicity against human SK-N-MC cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human SK-N-MC cells assessed as growth inhibition after 72 hrs by MTT assay
    		[PMID: 23276209]
    SK-N-MC IC50
    4.51 μM
    Compound: DFO
    Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay
    Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay
    		[PMID: 17602603]
    SK-N-MC IC50
    5 μM
    Compound: DFO
    Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay
    Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay
    		[PMID: 19601577]
    SK-N-MC IC50
    7.35 μM
    Compound: DFO
    Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay
    Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay
    		[PMID: 19216562]
    SK-N-MC IC50
    8.58 μM
    Compound: DFO
    Antiproliferative activity against human SK-N-MC cells after 96 hrs by MTT assay
    Antiproliferative activity against human SK-N-MC cells after 96 hrs by MTT assay
    		[PMID: 17064069]
    SK-N-MC IC50
    9.89 μM
    Compound: DFO
    Cytotoxicity against human SK-N-MC cells after 72 hrs by MTT assay
    Cytotoxicity against human SK-N-MC cells after 72 hrs by MTT assay
    		[PMID: 20303768]
    U2OS EC50
    17.8 μM
    Compound: DFO
    Activation of human HIF1alpha expressed in DFX-induced human U2OS cells incubated for 30 mins prior to DFX-induction measured after overnight incubation by luciferase reporter gene assay
    Activation of human HIF1alpha expressed in DFX-induced human U2OS cells incubated for 30 mins prior to DFX-induction measured after overnight incubation by luciferase reporter gene assay
    		[PMID: 22172704]
    U373-MAGI CC50
    > 400 μM
    Compound: Deferoxamine
    Cytotoxicity against human U373-MAGI cells by CellTitre-Glo assay
    Cytotoxicity against human U373-MAGI cells by CellTitre-Glo assay
    		[PMID: 24120088]
    U373-MAGI EC50
    384 μM
    Compound: Deferoxamine
    Antiviral activity against HIV1 infected in human U373-MAGI cells incubated for 2 hrs prior to viral infection followed by compound washout after 24 hrs measured 72 hrs post-infection by flow cytometry
    Antiviral activity against HIV1 infected in human U373-MAGI cells incubated for 2 hrs prior to viral infection followed by compound washout after 24 hrs measured 72 hrs post-infection by flow cytometry
    		[PMID: 24120088]
    體外研究
    (In Vitro)

    Deferoxamine（1 mM；16 小時(shí)或 4 周）可改善缺氧和高血糖條件下的 HIF-1α 功能并降低 MEFs 細(xì)胞中的 ROS[1]。
    Deferoxamine（100 μM；24 小時(shí)）可增加 InsR 表達(dá)和活性，同時(shí)誘導(dǎo) p-Akt/總 Akt/PKB 水平增加[2]。
    Deferoxamine（5、10、25、50、100 μM；7 或 9 天）可抑制腫瘤相關(guān) MSC 和骨髓 MSC 的增殖[3]。
    Deferoxamine（5、10、25、50、100 μM；7 天）誘導(dǎo) MSCs 凋亡[3]。
    Deferoxamine（10 μM；3 天）影響 MSCs 上粘附蛋白的表達(dá)[3]。
    Deferoxamine（100 μM；24 小時(shí)）誘導(dǎo) SH-SY5Y 細(xì)胞中由 HIF-1α 水平介導(dǎo)的自噬[4]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Western Blot Analysis[1]

    Cell Line: MEFs cells
    Concentration: 1 mM
    Incubation Time: 16 h (hypoxia condition); 4 weeks (hyperglycemic conditions)
    Result: Significantly attenuated the hyperglycemia-associated increase in ROS levels under hypoxic high glucose conditions.
    Notably increased normoxic HIF transactivation in MEFs under both high glucose and normal glucose conditions.

    Western Blot Analysis[2]

    Cell Line: HepG2 cells
    Concentration: 100 μM
    Incubation Time: 24 h
    Result: Showed a twofold increase of InsR mRNA levels in cells.
    Increased by twofold InsR binding activity at the half-maximal concentration of 1.1 nM.

    Cell Proliferation Assay[3]

    Cell Line: TAMSCs and BMMSCs (all isolated from Male C57BL/6J mice (8 week-old; EG-7 induced tumor model))
    Concentration: 5, 10, 25, 50, 100 μM
    Incubation Time: 7 days (TAMSCs); 9 days (BMMSCs).
    Result: Inhibited the growth of TAMSCs and BMMSCs, and most cells are died at day 7 or 9 when exposed to 50 and 100 μM dose.

    Apoptosis Analysis[3]

    Cell Line: TAMSCs, BMMSCs
    Concentration: 5, 10, 25, 50, 100 μM
    Incubation Time: 7 days
    Result: Exhibited proapoptotic effect on TAMSCs and BMMSCs cells.

    Western Blot Analysis[3]

    Cell Line: TAMSCs, BMMSCs
    Concentration: 10 μM
    Incubation Time: 3 days
    Result: Remarkably decreased VCAM-1 expression in both TAMSCs and BMMSCs.

    Cell Autophagy Assay[4]

    Cell Line: SH-SY5Y cells
    Concentration: 100 μM
    Incubation Time: 24 h
    Result: Increased the ratio of LC3-II/I, an indicator of autophagy, which effects were blocked when autophagy-related gene Beclin 1 was suppressed by Beclin 1 siRNA transfection.
    Caused a time and dose-dependent increase of HIF-1a, accompanied by the induction of autophagy.
    體內(nèi)研究
    (In Vivo)

    Deferoxamine（560.68 毫克/支；滴注；每天一次，持續(xù) 21 天）可促進(jìn)老年或糖尿病小鼠的傷口愈合并增加新生血管形成[1]。
    Deferoxamine（200 mg/kg；腹腔注射；每天一次，持續(xù) 2 周）可穩(wěn)定 HIF-1α，并增加葡萄糖攝取、肝臟 InsR 表達(dá)和體內(nèi)信號(hào)傳導(dǎo)[2]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Aged (21-month-old) and diabetic (12-week-old) C57BL/6J mice (excisional wound model)[1].
    Dosage: 560.68 mg/per (10 uL of 1 mM)
    Administration: Drip-on; once daily for 21 days.
    Result: Displayed significantly accelerated healing and increased neovascularization in both aged and diabetic mice model.
    Animal Model: Male Sprague-Dawley rats (180-200 g)[2].
    Dosage: 200 mg/kg
    Administration: Intraperitoneal injection; daily for 2 weeks.
    Result: Significantly increased hepatic HIF-1α protein levels, InsR protein levels, as well as Akt/PKB and activated Akt/PKB were significantly higher in the liver.
    Clinical Trial
    分子量

    560.68

    Formula

    C25H48N6O8
    CAS 號(hào)
    性狀

    固體

    顏色

    White to off-white

    中文名稱

    去鐵胺
    運(yùn)輸條件

    Room temperature in continental US; may vary elsewhere.
    儲(chǔ)存方式
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    溶解性數(shù)據(jù)
    細(xì)胞實(shí)驗(yàn)： 

    DMSO 中的溶解度 : 10 mg/mL (17.84 mM; 超聲助溶 (<60°C); 吸濕的 DMSO 對(duì)產(chǎn)品的溶解度有顯著影響，請(qǐng)使用新開封的 DMSO)

    配制儲(chǔ)備液
    濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg
    1 mM 1.7835 mL 8.9177 mL 17.8355 mL
    5 mM 0.3567 mL 1.7835 mL 3.5671 mL
    查看完整儲(chǔ)備液配制表

    * 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；一旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
    儲(chǔ)備液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)月內(nèi)使用，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)月內(nèi)使用。

    • 摩爾計(jì)算器

    • 稀釋計(jì)算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質(zhì)量
    =
    濃度
    ×
    體積
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    濃度 (start)

    C1

    ×
    體積 (start)

    V1

    =
    濃度 (final)

    C2

    ×
    體積 (final)

    V2

    動(dòng)物實(shí)驗(yàn)：

    請(qǐng)根據(jù)您的 實(shí)驗(yàn)動(dòng)物和給藥方式 選擇適當(dāng)?shù)娜芙夥桨浮?

    以下溶解方案都請(qǐng)先按照 In Vitro 方式配制澄清的儲(chǔ)備液，再依次添加助溶劑：
    ——為保證實(shí)驗(yàn)結(jié)果的可靠性，澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的工作液，建議您現(xiàn)用現(xiàn)配，當(dāng)天使用；
    以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過(guò)加熱和/或超聲的方式助溶

    • 方案 一

      請(qǐng)依序添加每種溶劑： 10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 1.25 mg/mL (2.23 mM); 澄清溶液

      此方案可獲得 ≥ 1.25 mg/mL（飽和度未知）的澄清溶液。

      以 1 mL 工作液為例，取 100 μL 12.5 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水 定容至 1 mL。

      生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。
    • 方案 二

      請(qǐng)依序添加每種溶劑： 10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 1.25 mg/mL (2.23 mM); 澄清溶液

      此方案可獲得 ≥ 1.25 mg/mL（飽和度未知）的澄清溶液。

      以 1 mL 工作液為例，取 100 μL 12.5 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液 中，混合均勻。

      2 g SBE-β-CD（磺丁基醚 β-環(huán)糊精）粉末定容于 10 mL 的生理鹽水中，完全溶解至澄清透明。
    動(dòng)物溶解方案計(jì)算器
    請(qǐng)輸入動(dòng)物實(shí)驗(yàn)的基本信息：

    給藥劑量

    mg/kg

    動(dòng)物的平均體重

    g

    每只動(dòng)物的給藥體積

    μL

    動(dòng)物數(shù)量

    只
    由于實(shí)驗(yàn)過(guò)程有損耗，建議您多配一只動(dòng)物的量
    請(qǐng)輸入您的動(dòng)物體內(nèi)配方組成：
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    如果您的動(dòng)物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過(guò) 2%。
    方案所需 助溶劑 包括：DMSO， ，均可在 MCE 網(wǎng)站選購(gòu)。 ，Tween 80，均可在 MCE 網(wǎng)站選購(gòu)。
    計(jì)算結(jié)果
    工作液所需濃度 : mg/mL
    儲(chǔ)備液配制方法 : mg 藥物溶于 μL  DMSO（母液濃度為 mg/mL）。
    您所需的儲(chǔ)備液濃度超過(guò)該產(chǎn)品的實(shí)測(cè)溶解度，以下方案僅供參考，如有需要，請(qǐng)與 MCE 中國(guó)技術(shù)支持聯(lián)系。
    動(dòng)物實(shí)驗(yàn)體內(nèi)工作液的配制方法 : 取 μL DMSO 儲(chǔ)備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。
    連續(xù)給藥周期超過(guò)半月以上，請(qǐng)謹(jǐn)慎選擇該方案。
    請(qǐng)確保第一步儲(chǔ)備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱 （超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。
    純度 & 產(chǎn)品資料

    純度: 99.76%

    參考文獻(xiàn)

    完整儲(chǔ)備液配制表

    * 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；一旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
    儲(chǔ)備液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)月內(nèi)使用，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)月內(nèi)使用。

    可選溶劑 濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 1.7835 mL 8.9177 mL 17.8355 mL 44.5887 mL
    5 mM 0.3567 mL 1.7835 mL 3.5671 mL 8.9177 mL
    10 mM 0.1784 mL 0.8918 mL 1.7835 mL 4.4589 mL
    15 mM 0.1189 mL 0.5945 mL 1.1890 mL 2.9726 mL
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    您最近查看的產(chǎn)品:

    Your information is safe with us. * Required Fields.

       產(chǎn)品名稱：

    		  

    * 需求量：

    * 客戶姓名：

    		 

    * Email：

    * 電話：

    		 

    * 公司或機(jī)構(gòu)名稱：

       留言給我們：

    Bulk Inquiry

    Inquiry Information

    產(chǎn)品名稱：
    Deferoxamine
    目錄號(hào)：
    HY-B1625
    需求量：